

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **IMAGIN MEDICAL INC.** (the "Issuer").

Trading Symbol: **IME**

Number of Outstanding Listed Securities: **139,060,278**

Date: **November 30, 2018**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business. See news release as filed on CSE dated November 28, 2018.

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On November 28, 2018, the Company issued a news release regarding certain market activity surrounding its common shares.

On November 26, 2018, the Company was notified by the OTC Markets about certain promotional emails distributed in relation to its Common Shares from November 23 through November 26, 2018. Based on a review of the recent trading activity in the Common Shares, it appeared that the effect of these promotional emails may have been an increase in the volume of Common Shares traded on November 26, 2018 on the OTCQB. It is not, however, possible to accurately quantify this effect, and there was virtually no change in the closing price of the Common Shares on November 26, 2018.

After due inquiry, the Company confirmed that neither the Company nor any of its officers, directors or, to the knowledge of the Company, controlling shareholder (i.e. shareholders owning 10% or more of the Common Shares) or third-party service provider were involved, directly or

indirectly, with the creation and/or distribution of the promotional emails, nor did they authorize or pay for such. The promotional emails were created, distributed and paid for by an unknown and unaffiliated third party.

While it appeared from reviewing the promotional emails that certain statements and claims made therein were taken from the Company's website, historical press releases and other public documents, the Company did not have any editorial control over the content. Further, there were certain statements made in the promotional emails which encouraged investors to purchase the Common Shares. These statements expressed the views of the authors only and the Company disclaims any potentially exaggerated or misleading statements contained in the material. In addition, the Company determined that certain statements included in the promotional emails might be misleading and/or incomplete and cautioned recipients should not place undue reliance on these promotional emails. Specifically, the Company stated that it did not condone the use of sensational language to describe its business prospects or growth potential within its industry. The Company further stated that it does not condone any statements made regarding the urgency of investing in the Common Shares, or any other similar statements. Finally, the Company noted that investing in the Common Shares involves certain risks and uncertainties that investors should review prior to making any investment decision. The Company encouraged all investors to undertake proper due diligence and carefully consider all investment decisions. The Company directed potential investors to rely solely on its filings and disclosures made with Canadian securities regulators available at www.sedar.com and on the OTC Disclosure & News Service available at www.otcmarkets.com.

Since November 1, 2017, the Company has engaged the following providers of investor relations, public relations, advertising and other related services, including the advertising of the Company and its Common Shares: Capital Ideas Media, Bolero Companies, Johl Jetkar Consulting, Oceanpoint, Public Eye, Hybrid Capital, Financial Buzz, Tyler Media,

2. Provide a general overview and discussion of the activities of management. **The Company continued its ongoing work on product development and testing. The Company also responded to regulatory inquiries about recent trading activity in its common shares, by issuing its news release of November 28, 2018 (see above).**
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how

the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

8. Describe the acquisition of new customers or loss of customers.
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
11. Report on any labour disputes and resolutions of those disputes if applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
14. Provide details of any securities issued and options or warrants granted (cancelled).

The following shares were issued from Treasury in the month of November, 2018, pursuant to the exercise of outstanding warrants.

Security	Number Issued	Details of Issuance	Use of Proceeds
Common Shares	37,500	Warrants exercised @ \$0.16	G&A
Common Shares	2,000	Finders' warrants exercised @ \$0.16	G&A

(1) State aggregate proceeds and intended allocation of proceeds. Gross proceeds of \$6,320 allocated for G & A.

15. Provide details of any loans to or by Related Persons. **NIL**
16. Provide details of any changes in directors, officers or committee members.
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 4, 2018.


John Vacha

Name of Director or Senior Officer

Signature

Chief Financial Officer

Official Capacity

Issuer Details Name of Issuer IMAGIN MEDICAL INC.	For Month End November 2018	Date of Report YY/MM/D December 4, 2018
Issuer Address 600 – 890 Pender St.		
City/Province/Postal Code Vancouver, B.C. V6C 1J9	Issuer Fax No.	Issuer Telephone No. 617-571-6006
Contact Name JIM HUTCHENS	Contact Position CEO	Contact Telephone No. 617-571-6006
Contact Email Address hutchens.j48@gmail.com	Web Site Address http://imaginmedical.com	